FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology. A group of inventions is described, including a recombinant oncolytic adenovirus (Ad) based on the human Ad6 strain Ad6, a method for treating a mammal with a malignant neoplasm, the use of a recombinant oncolytic adenovirus for the treatment of malignant neoplasms, and the use of a recombinant oncolytic adenovirus as a drug for the treatment of malignant neoplasms. In one embodiment, the recombinant oncolytic adenovirus comprises capsid hexon polypeptides wherein at least two hexon hypervariable region (HVR) polypeptides of a human Ad6 capsid hexon polypeptide are replaced with at least two HVR polypeptides from human Ad57 strain Ad57.
EFFECT: invention expands the arsenal of recombinant oncolytic adenoviruses.
27 cl, 71 dwg, 2 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MULTIVALENT PD-L1-BINDING COMPOUNDS FOR TREATING MALIGNANT NEOPLASMS | 2020 |
|
RU2816646C2 |
| ANTIBODIES TO DENGUE VIRUS, POLYPEPTIDES CONTAINING FC-REGION OPTIONS AND THEIR APPLICATION METHODS | 2017 |
|
RU2758596C2 |
| ANTIBODIES TO MYOSTATIN, POLYPEPTIDES CONTAINING FC-REGION VARIANTS, AND THEIR APPLICATION METHODS | 2016 |
|
RU2789884C2 |
| ANTIBODIES AGAINST SIGNAL-REGULATORY ALPHA PROTEIN AND THEIR APPLICATION METHODS | 2017 |
|
RU2771964C2 |
| ANTIBODIES TO DENGUE VIRUS WITH CROSS-REACTIVITY WITH ZIKA VIRUS | 2019 |
|
RU2811697C2 |
| ANTIBODIES TO MYOSTATIN AND THEIR APPLICATION METHODS | 2017 |
|
RU2778945C2 |
| ANTIBODIES TO MYOSTATIN, POLYPEPTIDES CONTAINING FC REGION VARIANTS AND METHODS OF THEIR USE | 2015 |
|
RU2799522C2 |
| COMBINATION THERAPY BASED ON T-CELL-ACTIVATING BISPECIFIC ANTIGEN-BINDING MOLECULES AGAINST CD3 AND FOLATE RECEPTOR 1 (FOLR1) AND ANTAGONISTS BINDING TO PD-1 AXIS | 2015 |
|
RU2753902C2 |
| C5 ANTIBODIES AND THEIR APPLICATION METHODS | 2015 |
|
RU2746356C2 |
| BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO PD1 AND LAG3 | 2018 |
|
RU2778805C2 |
